Skip to main navigation Skip to search Skip to main content

Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease

  • Thomas Jefferson University
  • University of Pennsylvania

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological syndrome associated with lung cancer, breast adenocarcinoma, ovarian adenocarcinoma, and Hodgkin disease. It is rarely seen in pediatrics. We report a case of a 10-year-old boy with a 2-year prodrome that led to a diagnosis of PCD in association with stage IV Hodgkin disease. He received radiation and chemotherapy for his Hodgkin disease with resolution of his lymphoma. Based on promising data in adults on the efficacy of rituximab over other immunosuppressive agents in paraneoplastic disorders, he was treated with rituximab with marked improvement of the cerebellar syndrome.

Original languageEnglish
Pages (from-to)986-987
Number of pages2
JournalPediatric Blood and Cancer
Volume58
Issue number6
DOIs
StatePublished - Jun 2012

Keywords

  • Hodgkin
  • Paraneoplastic cerebellar degeneration
  • Rituximab

Fingerprint

Dive into the research topics of 'Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease'. Together they form a unique fingerprint.

Cite this